Journal: Pharmaceutics

Article Title: New Vehiculation Systems of Mometasone Furoate for the Treatment of Inflammatory Skin Diseases

doi: 10.3390/pharmaceutics14122558

Figure Lengend Snippet: Structure of Mometasone furoate .

Article Snippet: Mometasone furoate (Carbosynth ® ), mometasone furoate commercial cream (1 mg/g Elocom ® cream), ethanol (Guinama ® ), glycerol (Acofarma ® ), Tween 80 (Scharlab S.L., Barcelona, Spain), vitamin E (Guinama ® ), PBS (VWR Life Science ® ) and hyaluronic acid (Carbosynth Limited (Compton, UK)), phorbol 1,2-myristate 1,3-acetate (Sigma-Aldrich, St. Louis, MI, USA), and all solvents of analytical grade were purchased from (Scharlab S.L).

Techniques:

Journal: Pharmaceutics

Article Title: New Vehiculation Systems of Mometasone Furoate for the Treatment of Inflammatory Skin Diseases

doi: 10.3390/pharmaceutics14122558

Figure Lengend Snippet: Composition of mometasone furoate-loaded vesicles.

Article Snippet: Mometasone furoate (Carbosynth ® ), mometasone furoate commercial cream (1 mg/g Elocom ® cream), ethanol (Guinama ® ), glycerol (Acofarma ® ), Tween 80 (Scharlab S.L., Barcelona, Spain), vitamin E (Guinama ® ), PBS (VWR Life Science ® ) and hyaluronic acid (Carbosynth Limited (Compton, UK)), phorbol 1,2-myristate 1,3-acetate (Sigma-Aldrich, St. Louis, MI, USA), and all solvents of analytical grade were purchased from (Scharlab S.L).

Techniques:

Journal: Pharmaceutics

Article Title: New Vehiculation Systems of Mometasone Furoate for the Treatment of Inflammatory Skin Diseases

doi: 10.3390/pharmaceutics14122558

Figure Lengend Snippet: Mean encapsulation efficiency, particle size, polydispersity index and Z potential of mometasone furoate-loaded vesicles.

Article Snippet: Mometasone furoate (Carbosynth ® ), mometasone furoate commercial cream (1 mg/g Elocom ® cream), ethanol (Guinama ® ), glycerol (Acofarma ® ), Tween 80 (Scharlab S.L., Barcelona, Spain), vitamin E (Guinama ® ), PBS (VWR Life Science ® ) and hyaluronic acid (Carbosynth Limited (Compton, UK)), phorbol 1,2-myristate 1,3-acetate (Sigma-Aldrich, St. Louis, MI, USA), and all solvents of analytical grade were purchased from (Scharlab S.L).

Techniques:

Journal: Pharmaceutics

Article Title: New Vehiculation Systems of Mometasone Furoate for the Treatment of Inflammatory Skin Diseases

doi: 10.3390/pharmaceutics14122558

Figure Lengend Snippet: Mean encapsulation efficiency, particle size, polydispersity index and Z potential of selected mometasone furoate-loaded vesicles. Data are represented as the mean values ± standard deviations ( n = 3). (NS no significative differences; * p < 0.05; *** p < 0.001.)

Article Snippet: Mometasone furoate (Carbosynth ® ), mometasone furoate commercial cream (1 mg/g Elocom ® cream), ethanol (Guinama ® ), glycerol (Acofarma ® ), Tween 80 (Scharlab S.L., Barcelona, Spain), vitamin E (Guinama ® ), PBS (VWR Life Science ® ) and hyaluronic acid (Carbosynth Limited (Compton, UK)), phorbol 1,2-myristate 1,3-acetate (Sigma-Aldrich, St. Louis, MI, USA), and all solvents of analytical grade were purchased from (Scharlab S.L).

Techniques:

Journal: Pharmaceutics

Article Title: New Vehiculation Systems of Mometasone Furoate for the Treatment of Inflammatory Skin Diseases

doi: 10.3390/pharmaceutics14122558

Figure Lengend Snippet: Mean particle size, polydispersity index and Z potential of selected mometasone furoate-loaded vesicles measured during 9 months of storage at 4 °C. Data are represented as the mean values ± standard deviations ( n = 3). (NS no significative differences; *** p < 0.001.)

Article Snippet: Mometasone furoate (Carbosynth ® ), mometasone furoate commercial cream (1 mg/g Elocom ® cream), ethanol (Guinama ® ), glycerol (Acofarma ® ), Tween 80 (Scharlab S.L., Barcelona, Spain), vitamin E (Guinama ® ), PBS (VWR Life Science ® ) and hyaluronic acid (Carbosynth Limited (Compton, UK)), phorbol 1,2-myristate 1,3-acetate (Sigma-Aldrich, St. Louis, MI, USA), and all solvents of analytical grade were purchased from (Scharlab S.L).

Techniques:

Journal: Pharmaceutics

Article Title: New Vehiculation Systems of Mometasone Furoate for the Treatment of Inflammatory Skin Diseases

doi: 10.3390/pharmaceutics14122558

Figure Lengend Snippet: Cell viability of keratinocytes treated for 48 h with mometasone furoate in dispersion or loaded in vesicles diluted to reach 1, 0.1, 0.01, and 0.001 μg/mL of drug. Data are reported as the mean values ± standard deviations of cell viability expressed as the percentage of untreated cells (100% of viability). The symbol * indicates values that were statistically different from control; the symbol ▴ indicates values that were statistically different from mometasone furoate dispersion; the symbol ◆ indicates values that were statistically different from glycerosomes ( p < 0.05).

Article Snippet: Mometasone furoate (Carbosynth ® ), mometasone furoate commercial cream (1 mg/g Elocom ® cream), ethanol (Guinama ® ), glycerol (Acofarma ® ), Tween 80 (Scharlab S.L., Barcelona, Spain), vitamin E (Guinama ® ), PBS (VWR Life Science ® ) and hyaluronic acid (Carbosynth Limited (Compton, UK)), phorbol 1,2-myristate 1,3-acetate (Sigma-Aldrich, St. Louis, MI, USA), and all solvents of analytical grade were purchased from (Scharlab S.L).

Techniques:

Journal: Pharmaceutics

Article Title: New Vehiculation Systems of Mometasone Furoate for the Treatment of Inflammatory Skin Diseases

doi: 10.3390/pharmaceutics14122558

Figure Lengend Snippet: Viability of keratinocytes stressed with hydrogen peroxide and protected with mometasone furoate in dispersion or loaded in vesicles properly diluted to reach 1, 0.1, 0.01, and 0.001 μg/mL of drug. Data are reported as the mean values ± standard deviations of cell viability expressed as the percentage of untreated cells (100% viability). The symbol * indicates values that were statistically different from control; the symbol ▴ indicates values that were statistically different from hydrogen peroxide; the symbol ◆ indicates values that were statistically different from mometasone furoate dispersion; the symbol ■ indicates values that were statistically different from glycerosomes; the symbol ★ indicates values that were statistically different from glyceroethosomes ( p < 0.05).

Article Snippet: Mometasone furoate (Carbosynth ® ), mometasone furoate commercial cream (1 mg/g Elocom ® cream), ethanol (Guinama ® ), glycerol (Acofarma ® ), Tween 80 (Scharlab S.L., Barcelona, Spain), vitamin E (Guinama ® ), PBS (VWR Life Science ® ) and hyaluronic acid (Carbosynth Limited (Compton, UK)), phorbol 1,2-myristate 1,3-acetate (Sigma-Aldrich, St. Louis, MI, USA), and all solvents of analytical grade were purchased from (Scharlab S.L).

Techniques:

Journal: Pharmaceutics

Article Title: New Vehiculation Systems of Mometasone Furoate for the Treatment of Inflammatory Skin Diseases

doi: 10.3390/pharmaceutics14122558

Figure Lengend Snippet: Representative images of mouse skin: untreated ( A ), damaged by TPA and treated with saline solution ( B ) or treated with mometasone furoate commercial cream ( C ), or mometasone furoate loaded in glycerosomes ( D ), glyceroethosomes ( E ) and glyceroethohyalurosomes ( F ).

Article Snippet: Mometasone furoate (Carbosynth ® ), mometasone furoate commercial cream (1 mg/g Elocom ® cream), ethanol (Guinama ® ), glycerol (Acofarma ® ), Tween 80 (Scharlab S.L., Barcelona, Spain), vitamin E (Guinama ® ), PBS (VWR Life Science ® ) and hyaluronic acid (Carbosynth Limited (Compton, UK)), phorbol 1,2-myristate 1,3-acetate (Sigma-Aldrich, St. Louis, MI, USA), and all solvents of analytical grade were purchased from (Scharlab S.L).

Techniques:

Journal: Pharmaceutics

Article Title: New Vehiculation Systems of Mometasone Furoate for the Treatment of Inflammatory Skin Diseases

doi: 10.3390/pharmaceutics14122558

Figure Lengend Snippet: Myeloperoxidase (MPO) concentration in mice untreated (Control), exposed to TPA and treated with saline (TPA) or treated with mometasone furoate commercial cream (Cream), or mometasone furoate loaded in glycerosomes (D), glyceroethosomes (E) and glyceroethohyalurosomes (F). Mean values ± standard deviations are reported. The symbol * indicates same values as mometasone furoate commercial cream ( p > 0.05).

Article Snippet: Mometasone furoate (Carbosynth ® ), mometasone furoate commercial cream (1 mg/g Elocom ® cream), ethanol (Guinama ® ), glycerol (Acofarma ® ), Tween 80 (Scharlab S.L., Barcelona, Spain), vitamin E (Guinama ® ), PBS (VWR Life Science ® ) and hyaluronic acid (Carbosynth Limited (Compton, UK)), phorbol 1,2-myristate 1,3-acetate (Sigma-Aldrich, St. Louis, MI, USA), and all solvents of analytical grade were purchased from (Scharlab S.L).

Techniques: Concentration Assay

Journal: Pharmaceutics

Article Title: New Vehiculation Systems of Mometasone Furoate for the Treatment of Inflammatory Skin Diseases

doi: 10.3390/pharmaceutics14122558

Figure Lengend Snippet: Representative images of the histological determination of mouse skin: untreated ( A ), damaged by TPA and treated with saline solution ( B ) or treated with mometasone furoate commercial cream ( C ), furoate loaded in glycerosomes ( D ), glyceroethosomes ( E ) and glyceroethohyalurosomes ( F ).

Article Snippet: Mometasone furoate (Carbosynth ® ), mometasone furoate commercial cream (1 mg/g Elocom ® cream), ethanol (Guinama ® ), glycerol (Acofarma ® ), Tween 80 (Scharlab S.L., Barcelona, Spain), vitamin E (Guinama ® ), PBS (VWR Life Science ® ) and hyaluronic acid (Carbosynth Limited (Compton, UK)), phorbol 1,2-myristate 1,3-acetate (Sigma-Aldrich, St. Louis, MI, USA), and all solvents of analytical grade were purchased from (Scharlab S.L).

Techniques:

Journal: Scientific reports

Article Title: A multiparametric screen uncovers FDA-approved small molecules that potentiate the nuclear mechano-dysfunctions in ATR-defective cells.

doi: 10.1038/s41598-024-80837-w

Figure Lengend Snippet: Fig. 3. Analysis of the cellular mechanical properties of HeLa shATR cells treated with ‘worsening’ compounds. (a) Elastic modulus measurements using AFM. Cellular stiffness was measured on shATR HeLa cells treated for 24 h with DMSO or the indicated compounds: Olaparib and Mometasone were tested at 10 μM, Dasatinib at 1 μM. At least 50 cells were detected in three independent experiments. (b) Quantification of nuclear to cytoplasmic YAP signal ratio. shATR HeLa cells were treated with the indicated compounds at two doses for 24 h, then fixed and stained for YAP. The ratio of nuclear and cytoplasmic intensity signals was calculated after background subtraction. Data is reported as mean ± SD of three independent experiments with at least 3 technical replicates for the treated samples and at least 12 technical replicates for the controls in each experiment. **p ≤ 0.01, ****p ≤ 0.0001 by ordinary one-way ANOVA test using Bonferroni’s correction for multiple comparisons. (c) Immunofluorescence images showing YAP cellular distribution under the indicated conditions. Scale bar 20 μm.

Article Snippet: For the Confirmation some selected compounds were repurchased from Selleck Chemicals: Mometasone furoate (S1987), Dasatinib (S1021), Olaparib (AZD2281, Ku-0059436) (S1060), PF-477736 (S2904), Ruxolitinib (S1378), Y-39983 Dihydrochloride (S7935), Abemaciclib (S5716), GW3965 HCl (S2630), Everolimus (S1120).

Techniques: Staining, Immunofluorescence

Journal: Scientific reports

Article Title: A multiparametric screen uncovers FDA-approved small molecules that potentiate the nuclear mechano-dysfunctions in ATR-defective cells.

doi: 10.1038/s41598-024-80837-w

Figure Lengend Snippet: Fig. 7. The ‘worsening’ compounds stimulate a cGAS-STING-mediated inflammatory ISG response in HCC1937 cells when combined with AZD6738. Heat-map graph showing the induction of a selected panel of ISG genes normalized to the DMSO condition in HCC1937 cells treated with ATRi AZD6738 3 μM for 48 h; AZD6738 was administered alone or in combination with the ‘worsening’ compounds (24 h treatment). Mometasone and Olaparib were tested at 10 μM, while PF-477736 and Dasatinib were tested at 1 μM and 0.1 μM respectively. Bar graphs show the ISG induction levels as an average of three independent biological replicates (left panel). Statistical analysis by ordinary one-way ANOVA test using Bonferroni’s correction for multiple was applied, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.

Article Snippet: For the Confirmation some selected compounds were repurchased from Selleck Chemicals: Mometasone furoate (S1987), Dasatinib (S1021), Olaparib (AZD2281, Ku-0059436) (S1060), PF-477736 (S2904), Ruxolitinib (S1378), Y-39983 Dihydrochloride (S7935), Abemaciclib (S5716), GW3965 HCl (S2630), Everolimus (S1120).

Techniques:

Journal: Polymers

Article Title: Recent Applications of PLGA in Drug Delivery Systems

doi: 10.3390/polym16182606

Figure Lengend Snippet: List of commercial PLGA drug delivery products approved by the FDA.

Article Snippet: Propel ® Intersect ENT, Inc., Menlo Park, CA, USA , Mometasone furoate , Implant , Chronic sinusitis , 0.37 mg per month.

Techniques: In Situ

Journal: Pharmaceutics

Article Title: Sinonasal Stent Coated with Sustained-Release Varnish of Mometasone Furoate Inhibits Pro-Inflammatory Cytokine Release from Macrophages: An In Vitro Study

doi: 10.3390/pharmaceutics15031015

Figure Lengend Snippet: A549 lung carcinoma cells were exposed to different concentrations of MMF (0.1, 1 µg/mL and 10 µg/mL) and 2.5 ng/mL IL-1β for 24 h. The GM-CSF levels in the supernatant were determined by an ELISA. MMF suppressed the IL-1β-induced GM-CSF production in A549 lung cancer cells. The lowest concentrations of mometasone (0.1–1 µg/mL) caused strong and similar inhibition of GM-CSF production, while the higher concentration of 10 µg/mL MMF had no effect. The values are the average of triplicates, and the standard deviation is presented. * p < 0.05.

Article Snippet: The following day, the medium was replaced with 100 µL of a fresh DMEM without FCS in the absence or presence of various concentrations of prednisone (P6254, Sigma, St. Louis, MO, USA) or mometasone furoate (M2343, Tokyo Chemical Industry, Tokyo, Japan).

Techniques: Enzyme-linked Immunosorbent Assay, Inhibition, Concentration Assay, Standard Deviation

Journal: Pharmaceutics

Article Title: Sinonasal Stent Coated with Sustained-Release Varnish of Mometasone Furoate Inhibits Pro-Inflammatory Cytokine Release from Macrophages: An In Vitro Study

doi: 10.3390/pharmaceutics15031015

Figure Lengend Snippet: A cellular model of inflammation. RAW264.7 macrophages were exposed to different concentrations of MMF (0.1, 1 µg/mL and 10 µg/mL) in the presence of 10 ng/mL LPS for 24 h. The levels of TNFα ( A ) and IL-6 ( B ) in the macrophage supernatants were determined by an ELISA. Mometasone suppressed both TNFα and IL-6 secretion from LPS-exposed macrophages. The macrophages produced a low amount of TNFα and IL-6 in the absence of LPS, which was strongly induced in its presence. The lower tested concentrations of MMF (0.1–1 µg/mL) caused stronger inhibition of TNFα than the higher one (10 µg/mL). The values are the average of triplicates, and the standard deviation is presented. * p < 0.05 compared to LPS alone.

Article Snippet: The following day, the medium was replaced with 100 µL of a fresh DMEM without FCS in the absence or presence of various concentrations of prednisone (P6254, Sigma, St. Louis, MO, USA) or mometasone furoate (M2343, Tokyo Chemical Industry, Tokyo, Japan).

Techniques: Enzyme-linked Immunosorbent Assay, Produced, Inhibition, Standard Deviation

Journal: Journal of controlled release : official journal of the Controlled Release Society

Article Title: Porous silicon embedded in a thermoresponsive hydrogel for intranasal delivery of lipophilic drugs to treat rhinosinusitis

doi: 10.1016/j.jconrel.2023.09.045

Figure Lengend Snippet: Schematic showing preparation of the composite drug delivery system used in this work, consisting of porous silicon (pSi) particles loaded with the corticosteroid drug mometasone furoate (MF) and dispersed in a thermoresponsive polymeric hydrogel: (a) MF-loaded pSi is mixed with the tri-block polymer poloxamer 407 (P407) to form the MF@pSi-HG formulation. (b) the MF@pSi-HG composite exists as a liquid at storage temperature (4–8 °C), allowing it to be delivered as a spray. The liquid then solidifies to a gel when the temperature rises to a range corresponding to those found in the nasal cavity (30–34 °C). Gelation occurs because P407 transitions into a micellar form. (c) Digital photographs of the MF@pSi-HG system in a liquid state at 8 °C (storage temperature) and viscous-gel state at 32 °C (nasal cavity temperature).

Article Snippet: Mometasone furoate (MF) was purchased from Adooq Bioscience (USA, Irvine, CA).

Techniques: Blocking Assay, Polymer, Formulation

Journal: Journal of controlled release : official journal of the Controlled Release Society

Article Title: Porous silicon embedded in a thermoresponsive hydrogel for intranasal delivery of lipophilic drugs to treat rhinosinusitis

doi: 10.1016/j.jconrel.2023.09.045

Figure Lengend Snippet: (a) FE-SEM image of pSi particles showing plate-like particles with a characteristic unidirectional pore morphology. A plan-view image of a single particle, showing the pore texture, is shown in the inset. (b) Hydrodynamic diameter (from dynamic light scattering measurement) of representative pSi particles, showing an average particle size of 875 nm. Cryo-SEM images of the hydrogel system prepared using (c) free mometasone furoate (0.5MF@HG), and (d) MF-loaded pSi particles (0.5-MF@pSi-HG).

Article Snippet: Mometasone furoate (MF) was purchased from Adooq Bioscience (USA, Irvine, CA).

Techniques: Single Particle

Journal: Journal of controlled release : official journal of the Controlled Release Society

Article Title: Porous silicon embedded in a thermoresponsive hydrogel for intranasal delivery of lipophilic drugs to treat rhinosinusitis

doi: 10.1016/j.jconrel.2023.09.045

Figure Lengend Snippet: Temporal in-vitro release curves comparing cumulative release of mometasone furoate (MF) from hydrogel samples that contained either MF-loaded pSi particles or an equivalent mass of pure MF. Elution studies were performed at 34 °C, with the formulation contained in a sealed dialysis bag with simulated nasal fluid (SNF) in the receptor medium. The amount of hydrogel formulation in each dialysis bag was 500 μL. (a) cumulative MF release from 0.1-MF@HG (green) and 0.1-MF@pSi-HG (blue), (b) cumulative MF release from 0.2-MF@HG (green) and 0.2-MF@pSi-HG (black), and (c) cumulative MF release from 0.5-MF@HG (green) and 0.5-MF@pSi-HG (red). Data for each MF release time point is presented as mean ± SD of three independent experiments and was analysed by t -test comparing the difference of means of corresponding composite hydrogels and controls (* = P < 0.05).

Article Snippet: Mometasone furoate (MF) was purchased from Adooq Bioscience (USA, Irvine, CA).

Techniques: In Vitro, Formulation

Journal: Journal of controlled release : official journal of the Controlled Release Society

Article Title: Porous silicon embedded in a thermoresponsive hydrogel for intranasal delivery of lipophilic drugs to treat rhinosinusitis

doi: 10.1016/j.jconrel.2023.09.045

Figure Lengend Snippet: Infiltration of mometasone furoate (MF) into human nasal mucosal tissue from pSi microparticle-containing hydrogels (0.1-MF@pSi-HG) and from control hydrogels containing free MF (0.1-MF@HG). Deposition of MF is quantified per gram of nasal tissue, measured 2 h, 4 h, 6 h, and 8 h after application of the relevant formulation. Both formulation types contain the same mass of MF. A gradual increase in the amount of drug deposited with time is observed for the 0.1-MF@pSi-HG formulation, while the 0.1-MF@HG control deposits a substantially lower amount (almost 19-times less) of drug per gram of nasal tissue over the 8 h span of the experiment. Data at each time point is presented as mean ± SD of three independent experiments and t -test indicated that difference of means of 0.1MF@pSi-HG and 0.1MF@HG at each time point was statistically significant (*** P < 0.0005).

Article Snippet: Mometasone furoate (MF) was purchased from Adooq Bioscience (USA, Irvine, CA).

Techniques: Control, Formulation

Journal: Advanced drug delivery reviews

Article Title: PLA Micro- and Nano-Particles

doi: 10.1016/j.addr.2016.05.020

Figure Lengend Snippet: Sustained release depot formulations based on PLGA/PLA currently available for clinical use.

Article Snippet: Propel TM (2012) Mometasone furoate Intersect ENT Post surgical Inflammation Implant Local delivery Lupaneta Pack (2012) Leuprolide acetate Norethindrone acetate AbbVie endocrine Prostate cancer Microparticle I.M.

Techniques: Formulation, In Situ

Journal: Evidence-based Complementary and Alternative Medicine : eCAM

Article Title: Anti-Inflammatory Effect of Qingpeng Ointment in Atopic Dermatitis-Like Murine Model

doi: 10.1155/2013/907016

Figure Lengend Snippet: Comparisons of AD-like skin lesions in BALB/c mice after a 2-week treatment. (a1) Normal mouse; (b1) model mouse; (c1) mouse treated with vehicle; (d1) 50% QP-treated mouse; (e1) 75% QP-treated mouse; (f1) 100% QP-treated mouse; (g1) MF-treated mouse. (a)–(g) were histopathology of corresponding skin. Significant erythema, desquamation, and crusting could be seen on the dorsal skin of model group and lessened significantly in all treated groups. Thickening of the epidermis and inflammatory cell accumulation could be seen in model group but was relieved in QP-treated groups in a dose-related pattern. QP: Qingpeng ointment; MF: Mometasone Furoate cream.

Article Snippet: The experimental groups were then treated, respectively, with vehicle of QP, 50% QP in vehicle, 75% QP in vehicle, 100% QP, and Mometasone Furoate cream (MF) (ELOSON, Merck Sharp & Dohme, USA) for 2 weeks after the model was established.

Techniques: Histopathology

Journal: Evidence-based Complementary and Alternative Medicine : eCAM

Article Title: Anti-Inflammatory Effect of Qingpeng Ointment in Atopic Dermatitis-Like Murine Model

doi: 10.1155/2013/907016

Figure Lengend Snippet: Comparisons of expression of serum IgE, tissue IFN- γ , and IL-4. (a) ELISA result of serum IgE; (b) ELISA result of IFN- γ ; (c) ELISA result of IL-4. * P < 0.05, ** P < 0.01 versus model group. QP: Qingpeng ointment; MF: Mometasone Furoate cream. # P < 0.05, ## P < 0.01 versus QP vehicle.

Article Snippet: The experimental groups were then treated, respectively, with vehicle of QP, 50% QP in vehicle, 75% QP in vehicle, 100% QP, and Mometasone Furoate cream (MF) (ELOSON, Merck Sharp & Dohme, USA) for 2 weeks after the model was established.

Techniques: Expressing, Enzyme-linked Immunosorbent Assay

Journal: Evidence-based Complementary and Alternative Medicine : eCAM

Article Title: Anti-Inflammatory Effect of Qingpeng Ointment in Atopic Dermatitis-Like Murine Model

doi: 10.1155/2013/907016

Figure Lengend Snippet: The changes of mRNA levels of IL-17A. The primary value of CT was transferred into 2 −ΔΔCT . ** P < 0.01 versus model group. MF: Mometasone Furoate cream; QP: Qingpeng ointment. ## P < 0.01 versus QP vehicle.

Article Snippet: The experimental groups were then treated, respectively, with vehicle of QP, 50% QP in vehicle, 75% QP in vehicle, 100% QP, and Mometasone Furoate cream (MF) (ELOSON, Merck Sharp & Dohme, USA) for 2 weeks after the model was established.

Techniques: